3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Etoposide
18
Carboplatin
18
pembrolizumab
15
Nivolumab
11
Cisplatin
11
atezolizumab
8
Topotecan
8
Irinotecan
7
Temozolomide
6
Paclitaxel
5
PM 01183
5
Ipilimumab
5
Gemcitabine
5
olaparib
4
Radiotherapy
4
Docetaxel
4
surufatinib
3
durvalumab
3
carfilzomib
3
Bevacizumab
3
veliparib
2
trilaciclib
2
sacituzumab govitecan
2
rovalpituzumab tesirine
2
obatoclax
2
niraparib
2
navitoclax
2
lorvotuzumab mertansine
2
lenvatinib
2
fluzoparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Small Cell Lung Carcinoma
×
rilotumumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts